
With mega merger season in full swing, Takeda officially swallows Shire
Amidst a flurry of multi-billion dollar mergers in 2019, the biggest-ever overseas acquisition by a Japanese drugmaker was consummated on Tuesday, as Takeda closed its $62 billion takeover of rare disease specialist Shire.
First discussed in March 2018, the deal that expands Takeda’s footprint in the world’s biggest market for drugs — the United States — and creates an entity with combined revenues of more than $30 billion was concluded despite an internal revolt by old timers in the Takeda shareholder base that cast doubt on the value of the transaction considering the size of the Dublin-based company’s debt.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.